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Abstract 
Purpose: To prepare some 2-morpholinomethylamino-4-(7-unsubstituted/substitutedcoumarin-3-yl)-6-
chlorosubstitutedphenyl pyrimidines as antimicrobial agents. 
Methods: Some 2-morpholinomethylamino-4-(7-unsubstituted/substitutedcoumarin-3-yl)-6-chloro-
substitutedphenyl pyrimidines were prepared by reacting 2-amino-4-(7-substituted/unsubstituted 
coumarin-3-yl)-6-(chlorosubstitutedphenyl) pyrimidines with morpholine and formaldehyde. The 
chemical structures of the synthesized compounds were elucidated by their Fourier Transform infra-red 
(FTIR), 1H-nuclear magnetic resonance (1H-NMR) and mass spectra, as well as by elemental analysis. 
These compounds were investigated for their antimicrobial activity against ten bacteria and five fungi by 
serial plate dilution method using the standard drugs, ofloxacin and ketoconazole, respectively, and 
their minimum inhibitory concentrations (MICs) were determined. 
Results:  A total of eighteen new compounds (1a-18a) were synthesized. Compound 3a (MIC = 75 
µg/mL; p < 0.0001) and 15a (MIC = 125 µg/mL; p < 0.001) produced stronger antifungal activity than the 
standard drug, ketoconazole (MIC = 25 µg/mL; p < 0.0001) against P. citrinum.  Compound 4a 
displayed higher but moderate activity against Gram-positive bacterium, S. aureus (MIC = 100 μg/mL; p 
< 0.05) than the standard drug, ofloxacin (MIC = 25 µg/mL; p < 0.0001).  Compound 4a also displayed 
higher but moderate activity against the Gram-negative bacterium, E. coli (MIC = 75 μg/mL; p < 0.0001) 
than the standard drug, ofloxacin (MIC = 12.5 µg/mL; p < 0.0001). The structure activity relationship 
analysis revealed that the chloro- substitution at position 2 of the phenyl ring along with a chlorobromo-
substituted coumarin moiety of the synthesized compounds is critical for activity against Gram-positive 
bacteria, Gram negative bacteria and fungi. 
Conclusion: The synthesized compounds are relatively active antifungal agents but are weak 
antibacterial agents. However, they require further evaluation of their antifungal activity against other 
fungal strains to ascertain their broad spectrum activity.  
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INTRODUCTION 
 
Microbial infections have been creating problems 
for mankind since centuries and scientists have 
also developed a large number of antimicrobial 
agents for the treatment of these infections. 
According to one new report, about 40 new 
microbial diseases have been identified since 
1970s and more than 2 million Americans are 
suffering from antibiotic resistance, of which 
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about 23,000 die each year [1]. Because of the 
development of antibiotic resistance and 
emergence of new microbial diseases, there is a 
need to develop new antimicrobial agents for the 
treatment of microbial infections. 
 
Pyrimidine derivatives have an important place in 
medicinal chemistry as these are associated with 
a broad range of biological activities [2-4] 
including antioxidant activity [5-7] and 
antimicrobial activity [8-13]. The clinical 
importance of pyrimidine nucleus is also evident 
by the marketing of clinically used pyrimidine 
derivatives as well as fused pyrimidine 
derivatives, for example, as antineoplastic agent 
(Tegafur), as vasodilator (Dipyridamole), as 
expectorant (Tasuldine) and as antibacterial 
agent (Trimethoprim, Piromidic Acid, 
Tetroxoprim, Metioprim), as antifungal agent 
(Flucytosine), and as antiviral agent (Broxuridine, 
Idoxuridine) [14]. Recently, the significance and 
biological importance of pyrimidine derivatives 
including their clinical applications in the 
microbial world has been reviewed [15]. The 
antimicrobial activity of pyrimidine derivatives 
against broad range of microbes makes it an 
important skeleton in medicinal chemistry and 
drug development against microbes. Morpholine 
nucleus is an integral part of linezolid, a clinically 
used drug for the treatment of infections caused 
by gram-positive bacteria [16]. A number of 
morpholine containing chemical compounds 
have also been reported as antimicrobial agents 
[17-22]. Encouraged by these observations and 
also in continuation of our search for potent 
antimicrobial agents [23,24] including 
antimicrobial agents having coumarin moiety 
[25,26], we decided to prepare some 2-
morpholinomethylamino-4-(7-
unsubstituted/substitutedcoumarin-3-yl)-6-
chlorosubstitutedphenyl pyrimidines, herein after 
the title compounds (1a-18a), as antimicrobial 
agents.  
 
EXPERIMENTAL  
 
General 
 
Melting points were measured in open capillary 
tubes and are uncorrected. IR (KBr) spectra were 
recorded on a Nicolet, 5PC FT-IR spectrometer 
(Browser Morner, USA) and 1H-NMR spectra on 
a Bruker DRX-300 FT NMR (Bruker, Germany) 
spectrophotometer using TMS as internal 
reference (chemical shift in δ ppm). Mass spectra 
were recorded on a Jeol-JMS-D-300 mass 
spectrometer (70 eV) (Jeol, Japan). Satisfactory 
analysis for C, H, and N was obtained for the 
compounds within ± 0.4 % of the theoretical 
values. Purity of the compounds was checked on 
silica gel G plates using iodine vapours as 
visualizing agent. Rf value of the compounds was 
determined by using a mixture of benzene and 
acetone (9:1). All reagents used in the present 
work were of analytical grade. The synthetic 
pathway for the preparation of the title 
compounds (1a-18a) is provided in Fig. 1. 
 
The 2-amino-4-(7-substituted/unsubstituted 
coumarin-3-yl)-6-(chlorosubstitutedphenyl) 
pyrimidines (1-18) prepared according to our 
previous report [25] were reacted with 
morpholine and formaldehyde in absolute 
ethanol to provide the title compounds (1a-18a). 
 
General method for the synthesis (1a-18a) 
 
A mixture of 2-amino-4-(7-unsubstituted/ 
substituted coumarin-3-yl)-6-chlorosubstituted 
phenyl pyrimidines (0.01 mole), morpholine (0.01 
mole) and formaldehyde (0.015 moles) was 
refluxed in absolute ethanol for 6 to 10 h. The 
reaction mixture was reduced to half of its 
volume and poured on crushed ice. The solid 
separated was filtered, washed with water 
repeatedly, dried and recrystallized from ethanol. 
 
Evaluation of antimicrobial activity 
 
The title compounds (1a-18a) were tested for 
their in vitro antimicrobial activity by serial plate 
dilution method [27,28] against Gram-positive 
bacteria, Staphylococcus aureus (ATCC 25923), 
Enterococcus faecalis (ATCC 29212), 
Staphylococcus epidermidis (ATCC 12228), 
Bacillus subtilis (ATCC 6633) and Bacillus 
cereus (ATCC 9946); Gram-negative bacteria, 
Escherichia coli (ATCC 25922), Pseudomonas 
aeruginosa (ATCC 27853), Klebsiella 
pneumoniae (ATCC 700603), Bordetella 
bronchiseptica (ATCC 4617) and Proteus 
vulgaris (ATCC 9920); fungi, Candida albicans 
(ATCC 2091), Aspergillus niger (MTCC 281), 
Aspergillus flavus (MTCC 277), Monascus 
purpureous (MTCC 369) and Penicillium citrinum 
(NCIM 768). 
 
The microorganisms were obtained from the 
Department of Microbiology, Majeedia Hospital, 
New Delhi, India. The Department of 
Microbiology of Majeedia Hospital obtained some 
of these microorganisms from the Institute of 
Genomics and Integrative Biology, New Delhi, 
India. 
 
Imran et al 
Trop J Pharm Res, February 2016; 15(2): 395  
 
X OH
CHO
+
CH3
O
O
OEt
EtOH
Piperidine
X O O
O
CH3
EtOH
Piperidine Ar-CHO
X O O
O
Ar 
Guanidine Carbonate
EtOH
X O O
N
N NH2
Ar 
(1 - 18)
EtOH
HCHO
ONH
X O O
N
N NH
Ar 
N
O
(1a - 18a)
Fig. 1. Synthesis of the title compounds  (1a-18a)
X = H, Cl, Br
(A) (B)
(C)
(D)
Ar = 2-chlorophenyl
4-chlorophenyl
2,6-dichlorophenyl
2,4-dichlorophenyl
2,5-dichlorophenyl
3,5-dichlorophenyl
3,4-dichlorophenyl
 
 
Nutrient agar medium and Sabouraud dextrose 
medium were used for antibacterial activity and 
antifungal activity, respectively. The compounds 
were tested at concentrations of 200, 175, 150, 
125, 100, 75, 50, 25 and 12.5 μg/mL. The 
reference or standard antibiotics, ofloxacin and 
ketoconazole, were used at 50, 25 and 12.5 
μg/mL concentrations for antibacterial activity 
and antifungal activity, respectively. Sterile 
dimethyl sulfoxide (DMSO) was used for the 
preparation of desired concentrations of the 
synthesized compounds and standard antibiotics.  
Sterile dimethyl sulfoxide without the synthesized 
compounds and standard antibiotics served as 
control group. The minimum inhibitory 
concentrations (MICs) values of the synthesized 
compounds, ofloxacin and ketoconazole, were 
also determined. The minimum inhibitory 
concentration (MIC) has been defined as the 
lowest concentration of a compound that 
inhibited visible growth of microorganisms on the 
plate. 
Statistical analysis 
 
All antimicrobial activity data are presented as 
mean ± SEM (n = 6). The data were analyzed by 
one-way analysis of variance (ANOVA) with 
Dunnett's Multiple Comparison Test with respect 
to control group and standard groups using 
GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego California USA). 
The results were considered significantly 
different at p < 0.05. 
 
RESULTS 
 
The title compounds (1a-18a) were prepared 
according to the method outlined in Fig 1. The 
characterization data of the intermediates, (C), 
(D) and (1-18) of the Fig. 1 were in line with our 
previously published data [25,26]. The structures 
of the title compounds (1a-18a) were confirmed 
on the basis of their IR, 1H-NMR, Mass and 
elemental analysis data. The appearance of the 
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IR absorption peaks from 3290 cm-1 to 3280 cm-1 
confirmed the stretching vibration of N-H group of 
–NH-CH2- moiety; from 1710 cm-1 to 1705 cm-1 
confirmed the stretching vibration of C=O group 
of the coumarin moiety; from 1611 cm-1 to 1604 
cm-1 confirmed the stretching vibration of C=N 
group of the pyrimidine ring; from 1545 cm-1 to 
1540 cm-1 confirmed the stretching vibration of 
C=C group of aromatic C=C bond; and from 
1135 cm-1 to 1130 cm-1 confirmed the stretching 
vibration of C-O-C group of coumarin moiety and 
morpholine moieties present in the title 
compounds (1a-18a). The appearance of the 
signals in the 1H-NMR spectra of the title 
compounds (1a-18a) at δ (ppm) values from 2.63 
to 2.72 confirmed four protons of –CH2-N-CH2- 
portion of the morpholine moiety; from 3.50 to 
3.58 confirmed four protons of –CH2-O-CH2- 
portion of the morpholin moiety; from 4.27 to 4.42 
confirmed two methylene protons of –NH-CH2- 
moiety; from 6.90 to 7.75 confirmed the number 
of aromatic protons; and from 7.80 to 789 
confirmed the secondary amino group 
(exchangeable with D2O) of –NH-CH2- moiety of 
the title compounds (1a-18a). The elemental 
analysis and molecular ion peaks of the title 
compounds (1a-18a) were also consistent with 
the assigned structures. The detailed physical 
constants, FTIR, 1H-NMR, mass and elemental 
analysis data of the title compounds (1a-18a) are 
presented as follows. 
 
2-(Morpholinomethylamino)-4-(coumarin-3-
yl)-6-(4-chlorophenyl) pyrimidine (1a) 
 
Yield: 55 %; m.p.: 147-149 oC; Rf: 0.76; IR (KBr) 
cm-1: 3289 (N-H), 1706 (C=O), 1607 (C=N), 1544 
(C=C), 1131 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.66 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.52 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.27 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.91-7.68 (m, 10H, Ar-
H), 7.86 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H21N4O3Cl), Found% 
(Calculated%): C, 64.20 (64.21); H, 4.72 (4.72); 
N, 12.47 (12.48); Mass (m/z): 448 (M+, 
C24H21N4O3Cl), 449 (M++1), 164 (100%, 
C9H7NCl). 
 
2-(Morpholinomethylamino)-4-(coumarin-3-
yl)-6-(2,6-dichlorophenyl)pyrimidine (2a) 
 
Yield: 55%; m.p.: 140-142 oC; Rf: 0.74; IR (KBr) 
cm-1: 3287 (N-H), 1707 (C=O), 1611 (C=N), 1543 
(C=C), 1133 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.69 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.57 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.32 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.93-7.73 (m, 9H, Ar-H), 
7.88 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H20N4O3Cl2), Found% 
(Calculated%): C, 59.62 (59.64); H, 4.17 (4.17); 
N, 11.58 (11.59). 
 
2-(Morpholinomethylamino)-4-(coumarin-3-
yl)-6-(2,4-dichlorophenyl)pyrimidine (3a) 
 
Yield: 50 %; m.p.: 155-157 oC; Rf: 0.71; IR (KBr) 
cm-1: 3287 (N-H), 1706 (C=O), 1607 (C=N), 1542 
(C=C), 1130 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.66 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.50 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 (d, J = 
12Hz, 2H, -NH-CH2-N-), 7.02-7.75 (m, 9H, Ar-H), 
7.84 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H20N4O3Cl2), Found% 
(Calculated%): C, 59.63 (59.64); H, 4.17 (4.17); 
N, 11.57 (11.59); Mass (m/z): 483 (M+, 
C24H20N4O3Cl2), 484 (M++1), 199 (100%, 
C9H6NCl2). 
 
2-(Morpholinomethylamino)-4-(coumarin-3-
yl)-6-(2-chlorophenyl)pyrimidine (4a) 
 
Yield: 55 %; m.p.: 147-149 oC; Rf: 0.77; IR (KBr) 
cm-1: 3286 (N-H), 1706 (C=O), 1605 (C=N), 1545 
(C=C), 1133 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.68 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.55 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 (d, J = 
12Hz, 2H, -NH-CH2-N-), 7.02-7.74 (m, 10H, Ar-
H), 7.88 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H21N4O3Cl), Found% 
(Calculated%): C, 64.20 (64.21); H, 4.71 (4.72); 
N, 12.47 (12.48). 
 
2-(Morpholinomethylamino)-4-(7-chlorocou-
marin-3-yl)-6-(4-chlorophenyl)pyrimidine (5a) 
 
Yield: 55 %; m.p.: 172-174 oC; Rf: 0.69; IR (KBr) 
cm-1: 3280 (N-H), 1705 (C=O), 1607 (C=N), 1544 
(C=C), 1130 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.69 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.53 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.90-7.71 (m, 9H, Ar-H), 
7.85 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H20N4O3Cl2), Found% 
(Calculated%): C, 59.62 (59.64); H, 4.16 (4.17); 
N, 11.57 (11.59); Mass (m/z): 483 (M+, 
C24H20N4O3Cl2), 484 (M++1), 164 (100%, 
C9H7NCl). 
 
2-(Morpholinomethylamino)-4-(7-bromocou-
marin-3-yl)-6-(4-chlorophenyl)pyrimidine (6a) 
 
Yield: 60 %; m.p.: 177-179 oC; Rf: 0.66; IR (KBr) 
cm-1: 3287 (N-H), 1710 (C=O), 1608 (C=N), 
1542 (C=C), 1132 (C-O-C); 1H-NMR (CDCl3, 
DMSO-d6)  ppm: 2.70 (t, J = 8Hz, 4H, -CH2-N-
CH2-), 3.54 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.39 
(d, J = 12Hz, 2H, -NH-CH2-N-), 6.90-7.69 (m, 
9H, Ar-H), 7.88 (s, 1H, NH, exchangable with 
D2O); Elemental Analysis (C24H20N4O3ClBr), 
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Found % (Calculated%): C, 54.60 (54.62); H, 
3.82 (3.82); N, 10.60 (10.62). 
 
2-(Morpholinomethylamino)-4-(7-chlorocou-
mrin-3-yl)-6-(2,6-dichlorophenyl)pyrimidine 
(7a) 
 
Yield: 50 %; m.p.: 185-187 oC; Rf: 0.69; IR (KBr) 
cm-1: 3290 (N-H), 1708 (C=O), 1608 (C=N), 
1544 (C=C), 1131 (C-O-C); 1H-NMR (CDCl3, 
DMSO-d6)  ppm: 2.71 (t, J = 8Hz, 4H, -CH2-N-
CH2-), 3.53 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.42 
(d, J = 12Hz, 2H, -NH-CH2-N-), 7.03-7.73 (m, 
8H, Ar-H), 7.88 (s, 1H, NH, exchangable with 
D2O); Elemental Analysis (C24H19N4O3Cl3), 
Found % (Calculated%): C, 55.66 (55.67); H, 
3.70 (3.70); N, 10.81 (10.82). 
2-(Morpholinomethylamino)-4-(7-bromocou-
marin-3-yl)-6-(2,6-dichlorophenyl)pyrimidine 
(8a) 
 
Yield: 55 %; m.p.: 171-173 oC; Rf: 0.66; IR (KBr) 
cm-1: 3287 (N-H), 1705 (C=O), 1610 (C=N), 1543 
(C=C), 1132 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.72 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.50 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.99-7.69 (m, 8H, Ar-H), 
7.86 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H19N4O3Cl2Br), Found % 
(Calculated%): C, 51.25 (51.27); H, 3.40 (3.41); 
N, 9.95 (9.96); Mass (m/z): 562 (M+, 
C24H19N4O3Cl2Br), 564 (M++2), 199 (100%, 
C9H6NCl2). 
 
2-(Morpholinomethylamino)-4-(7-chlorocou-
marin-3-yl)-6-(2,4-dichlorophenyl)pyrimidine 
(9a) 
 
Yield: 55 %; m.p.: 173-175 oC; Rf: 0.72; IR (KBr) 
cm-1: 3287 (N-H), 1706 (C=O), 1604 (C=N), 
1544 (C=C), 1130 (C-O-C); 1H-NMR (CDCl3, 
DMSO-d6)  ppm: 2.70 (t, J = 8Hz, 4H, -CH2-N-
CH2-), 3.51 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 
(d, J = 12Hz, 2H, -NH-CH2-N-), 7.03-7.74 (m, 
8H, Ar-H), 7.89 (s, 1H, NH, exchangable with 
D2O); Elemental Analysis (C24H19N4O3Cl3), 
Found % (Calculated%): C, 55.66 (55.67); H, 
3.70 (3.70); N, 10.82 (10.82). 
 
2-(Morpholinomethylamino)-4-(7-bromocou-
marin-3-yl)-6-(2,4-dichlorophenyl)pyrimidine 
(10a) 
 
Yield: 60 %; m.p.: 176-178 oC; Rf: 0.71; IR (KBr) 
cm-1: 3280 (N-H), 1705 (C=O), 1605 (C=N), 
1540 (C=C), 1133 (C-O-C); 1H-NMR (CDCl3, 
DMSO-d6)  ppm: 2.71 (t, J = 8Hz, 4H, -CH2-N-
CH2-), 3.55 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.42 
(d, J = 12Hz, 2H, -NH-CH2-N-), 7.04-7.70 (m, 
8H, Ar-H), 7.88 (s, 1H, NH, exchangable with 
D2O); Elemental Analysis (C24H19N4O3Cl2Br), 
Found % (Calculated%): C, 51.25 (51.27); H, 
3.40 (3.41); N, 9.95 (9.96). 
 
2-(Morpholinomethylamino)-4-(7-chlorocou-
marin-3-yl)-6-(2-chlorophenyl)pyrimidine (11a) 
 
Yield: 50 %; m.p.: 185-187 oC; Rf: 0.72; IR (KBr) 
cm-1: 3280 (N-H), 1705 (C=O), 1605 (C=N), 1542 
(C=C), 1130 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.69 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.58 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.37 (d, J = 
12Hz, 2H, -NH-CH2-N-), 7.01-7.74 (m, 9H, Ar-H), 
7.86 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H20N4O3Cl2), Found % 
(Calculated %): C, 59.63 (59.64); H, 4.16 (4.17); 
N, 11.58 (11.59). 
 
2-(Morpholinomethylamino)-4-(7-bromocou-
marin-3-yl)-6-(2-chlorophenyl)pyrimidine 
(12a) 
 
Yield: 55 %; m.p.: 176-178 oC; Rf: 0.76; IR (KBr) 
cm-1: 3280 (N-H), 1706 (C=O), 1606 (C=N), 
1544 (C=C), 1130 (C-O-C); 1H-NMR (CDCl3, 
DMSO-d6)  ppm: 2.70 (t, J = 8Hz, 4H, -CH2-N-
CH2-), 3.56 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 
(d, J = 12Hz, 2H, -NH-CH2-N-), 7.02-7.69 (m, 
9H, Ar-H), 7.88 (s, 1H, NH, exchangable with 
D2O); Elemental Analysis (C24H20N4O3ClBr), 
Found % (Calculated %): C, 54.61 (54.62); H, 
3.81 (3.82); N, 10.60 (10.62); Mass (m/z): 527 
(M+, C24H20N4O3ClBr), 529 (M++2), 164 (100 %, 
C9H7NCl). 
 
2-(Morpholinomethylamino)-4-(7-chlorocou-
marin-3-yl)-6-(2,5-dichlorophenyl)pyrimidine 
(13a) 
 
Yield: 45 %; m.p.: 190-192 oC; Rf: 0.82; IR (KBr) 
cm-1: 3288 (N-H), 1707 (C=O), 1609 (C=N), 1541 
(C=C), 1132 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.68 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.55 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.95-7.70 (m, 8H, Ar-H), 
7.88 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H19N4O3Cl3), Found % 
(Calculated%): C, 55.66 (55.67); H, 3.68 (3.70); 
N, 10.81 (10.82). 
 
2-(Morpholinomethylamino)-4-(7-bromocou-
marin-3-yl)-6-(2,5-dichlorophenyl)pyrimidine 
(14a) 
 
Yield: 50 %; m.p.: 210-212 oC; Rf: 0.75; IR (KBr) 
cm-1: 3283 (N-H), 1709 (C=O), 1611 (C=N), 1544 
(C=C), 1134 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.65 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
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3.51 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.29 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.99-7.72 (m, 8H, Ar-H), 
7.82 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H19N4O3Cl2Br), Found% 
(Calculated%): C, 51.26 (51.27); H, 3.40 (3.41); 
N, 9.95 (9.96). 
 
2-(Morpholinomethylamino)-4-(7-
chlorocoumarin-3-yl)-6-(3,5-
dichlorophenyl)pyrimidine (15a) 
 
Yield: 40 %; m.p.: 185-187 oC; Rf: 0.68; IR (KBr) 
cm-1: 3285 (N-H), 1705 (C=O), 1607 (C=N), 1541 
(C=C), 1133 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.63 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.54 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.39 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.97-7.68 (m, 8H, Ar-H), 
7.80 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H19N4O3Cl3), Found% 
(Calculated%): C, 55.65 (55.67); H, 3.69 (3.70); 
N, 10.80 (10.82); Mass (m/z): 517 (M+, 
C24H19N4O3Cl3), 518 (M++1), 199 (100%, 
C9H6NCl2). 
 
2-(Morpholinomethylamino)-4-(7-
bromocoumarin-3-yl)-6-(3,5-
dichlorophenyl)pyrimidine (16a) 
 
Yield: 55 %; m.p.: 173-175 oC; Rf: 0.73; IR (KBr) 
cm-1: 3281 (N-H), 1707 (C=O), 1610 (C=N), 1543 
(C=C), 1130 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.64 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.51 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.27 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.96-7.70 (m, 8H, Ar-H), 
7.83 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H19N4O3Cl2Br), Found % 
(Calculated %): C, 51.26 (51.27); H, 3.40 (3.41); 
N, 9.95 (9.96). 
 
2-(Morpholinomethylamino)-4-(7-
chlorocoumarin-3-yl)-6-(3,4-
dichlorophenyl)pyrimidine (17a) 
 
Yield: 45 %; m.p.: 160-162 oC; Rf: 0.71; IR (KBr) 
cm-1: 3286 (N-H), 1705 (C=O), 1606 (C=N), 1541 
(C=C), 1132 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.68 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.57 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.33 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.95-7.72 (m, 8H, Ar-H), 
7.85 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H19N4O3Cl3), Found % 
(Calculated %): C, 55.66 (55.67); H, 3.69 (3.70); 
N, 10.81 (10.82). 
 
2-(Morpholinomethylamino)-4-(7-
bromocoumarin-3-yl)-6-(3,4-
dichlorophenyl)pyrimidine (18a) 
 
Yield: 45 %; m.p.: 191-193 oC; Rf: 0.82; IR (KBr) 
cm-1: 3289 (N-H), 1709 (C=O), 1605 (C=N), 1544 
(C=C), 1135 (C-O-C); 1H-NMR (CDCl3, DMSO-
d6)  ppm: 2.66 (t, J = 8Hz, 4H, -CH2-N-CH2-), 
3.56 (t, J = 8Hz, 4H, -CH2-O-CH2-), 4.35 (d, J = 
12Hz, 2H, -NH-CH2-N-), 6.95-7.73 (m, 8H, Ar-H), 
7.88 (s, 1H, NH, exchangable with D2O); 
Elemental Analysis (C24H19N4O3Cl2Br), Found % 
(Calculated %): C, 51.26 (51.27); H, 3.40 (3.41); 
N, 9.95 (9.96); Mass (m/z): 562 (M+, 
C24H19N4O3Cl2Br), 564 (M++2), 199 (100%, 
C9H6NCl2). 
 
Antimicrobial activity 
 
The antimicrobial activity data of the title 
compounds (1a-18a) at different concentrations 
against Gram positive bacteria, Gram negative 
bacteria and fungi is provided in Table 1, Table 2 
and Table 3, respectively. For the explanation of 
the antimicrobial activity result this discussion, 
the zone of inhibition produced by the MIC of 
standard drugs, ofloxacin and ketoconazole, has 
been considered as 100 % for comparing the 
antibacterial activity and antifungal activity data 
of the title compounds (1a-18a), respectively. 
 
The antibacterial activity of ofloxacin against 
Gram positive bacteria revealed that it has a MIC 
value of 25 μg/mL against S. aureus, E. faecalis 
and S. epidermidis; and it has a MIC value of 
12.5 μg/mL against B. subtilis and B. cereus. The 
antibacterial activity of the title compounds (1a-
18a) with respect to ofloxacin revealed that the 
compound 4a (MIC = 100 μg/mL) displayed 
highest activity of about 93.98 % with p < 0.05 
against S. aureus; the compound 15a (MIC = 
125 μg/mL) displayed highest activity of about 
83.60 % with p < 0.0001 against E. faecalis; the 
compound 9a (MIC = 100 μg/mL) displayed 
highest activity of about 91.03 % (p < 0.0001) 
against S. epidermidis; the compound 14a (MIC 
= 150 μg/mL) displayed highest activity of about 
88.5 % with p < 0.0001 against B. subtilis; and 
the compound 18a (MIC = 100 μg/mL) displayed 
highest activity of about 91.45 % with p < 0.0001 
against B. cereus. 
 
Some compounds exhibited good but statistically 
non-significant antibacterial activity results (p > 
0.05) with respect to ofloxacin, for example, the 
compound 13a (MIC = 100 μg/mL) displayed 
about 99.88 % activity against S. aureus; 
compound 18a (MIC = 125 μg/mL) displayed 
about 94.75 % activity against S. aureus; and 
compounds 15a (MIC = 175 μg/mL) displayed 
about 98 % activity against S. epidermidis. The 
antibacterial activity produced by the compounds 
4a, 9a, 13a, 14a, 15a and 18a was lower than 
the antibacterial activity produced by ofloxacin  
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    Table 1: Antibacterial activity data of the title compounds (1a-18a) against Gram positive bacteria 
 
Compound Zone of inhibition (mm ± SD) and corresponding MIC (μg/mL) value in bracket  
S. aureus E. faecalis S. epidermidis B. subtilis B. cereus 
1a 12.28±0.27a (50) 17.12±0.26a (50) 16.82±0.26a (75) 10.50±0.30a (50) 18.77±0.24a (100) 
2a 10.73±0.23a (75) 20.67±0.29a (100) 9.20±0.23a (200) 16.53±0.25a (50) 13.97±0.28a (150) 
3a 17.02±0.32a (100) 13.53±0.33a (150) 16.55±0.29a (100) 18.07±0.31a (125) 20.28±0.27a (125) 
4a 24.20±0.30c (100) 20.38±0.30a (125) 24.08±0.26a (75) 21.05±0.31a (100) 24.78±0.32a (100) 
5a 13.27±0.28c (50) 11.62±0.28a (75) 19.72±0.33a (75) 14.62±0.42a (25) 19.92±0.28a (50) 
6a 5.27±0.26a (200) 17.48±0.28a (50) 16.12±0.36a (150) 22.05±0.29a (150) 13.95±0.24a (50) 
7a 11.08±0.33a (150) 14.02±0.16a (75) 19.20±0.32a (100) 15.05±0.24a (75) 22.97±0.22a (150) 
8a 20.22±0.25a (100) 16.42±0.27a (150) 11.63±0.51a (50) 15.27±0.36a (50) 21.38±0.39a (75) 
9a 21.62±0.41a (75) 23.22±0.37a (50) 25.08±0.35a (100) 19.97±0.33a (100) 21.15±0.40a (100) 
10a 14.80±0.42a (50) 12.25±0.34a (100) 18.65±0.35a (50) 19.50±0.31a (125) 9.23±0.39a (175) 
11a 9.72±0.43a (125) 16.65±0.38a (75) 14.03±0.31a (50) 12.07±0.36a (50) 20.02±0.33a (100) 
12a 20.62±0.33a (100) 11.80±0.37a (175) 9.28±0.40a (175) 17.02±0.42a (150) 23.57±0.41a (125) 
13a 25.72±0.36d (100) 21.13±0.36a (150) 19.30±0.38a (50) 25.17±0.45a (100) 25.65±0.30a (100) 
14a 21.87±0.43d (125) 18.83±0.41a (100) 24.02±0.26a (100) 27.95±0.29a (150) 22.80±0.34a (100) 
15a 20.20±0.35a (100) 24.02±0.39a (125) 27.00±0.26d (175) 16.77±0.40a (100) 19.15±0.41a (75) 
16a 14.98±0.37a (50) 18.50±0.25a (75) 12.08±0.47a (50) 8.48±0.41a (175) 18.20±0.35a (150) 
17a 18.95±0.28a (75) 13.98±0.27a (150) 21.03±0.27a (75) 15.38±0.37a (50) 24.27±0.31a (125) 
18a 24.40±0.36d (125) 21.53±0.38a (100) 24.05±0.28a (150) 4.63±0.39a (200) 26.43±0.36a (100) 
Ofloxacin 25.75±0.43a (25) 28.73±0.43a (25) 27.55±0.41a (25) 31.58±0.41a (12.5) 28.90±0.27a (12.5) 
Negative 
Control 
0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
       Values in parenthesis represent the corresponding MIC (μg/mL); ap < 0.0001, bp < 0.001, cp < 0.05, , dp > 0.05 
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    Table 2: Antibacterial activity data of the title compounds (1a-18a) against Gram negative bacteria 
 
Compound Zone of inhibition (mm ± SD and corresponding MIC (μg/mL)  
E. coli P. aeruginosa K. pneumonia B. bronchiseptica P. vulgaris 
1a 16.42±0.42a (100) 19.73±0.24a (100) 21.73±0.43a (75) 23.78±0.38a (100) 12.78±0.27a (200) 
2a 13.05±0.28a (150) 14.72±0.27a (150) 19.70±0.26a (125) 16.67±0.29a (50) 14.07±0.27a (50) 
3a 21.47±0.35a (75) 20.47±0.31a (75) 27.67±0.25a (100) 25.52±0.30a (125) 16.42±0.25a (50) 
4a 25.87±0.27a (75) 27.45±0.29a (50) 21.67±0.33a (75) 23.22±0.27a (100) 23.30±0.41a (100) 
5a 13.70±0.39a (175) 11.92±0.32a (200) 19.43±0.41a (50) 17.20±0.39a (150) 8.78±0.38a (175) 
6a 18.92±0.42a (100) 21.60±0.39a (75) 16.98±0.32a (50) 11.32±0.41a (200) 15.97±0.37a (75) 
7a 7.48±0.41a (200) 15.27±0.35a (150) 11.67±0.35a (150) 18.47±0.34a (75) 12.53±0.33a (150) 
8a 16.22±0.36a (50) 20.12±0.35a (100) 12.40±0.41a (125) 13.95±0.34a (175) 21.88±0.36a (100) 
9a 21.25±0.30a (100) 27.53±0.37a (100) 23.20±0.35a (100) 24.05±0.30a (100) 27.80±0.26a (75) 
10a 24.03±0.28a (100) 21.52±0.27a (50) 20.25±0.38a (100) 27.63±0.29a (100) 24.25±0.38a (100) 
11a 13.83±0.25a (150) 11.60±0.45a (75) 13.25±2.38a (175) 20.08±0.39a (150) 17.37±0.45a (50) 
12a 9.70±0.24a (200) 14.53±0.35a (50) 8.47±0.38a (75) 15.73±0.29a (150) 14.05±0.38a (50) 
13a 16.42±0.30a (50) 24.18±0.37a (75) 26.40±0.39a (75) 20.38±0.32a (125) 22.27±0.33a (75) 
14a 16.45±0.45a (50) 18.33±0.40a (75) 22.63±0.39a (100) 12.45±0.51a (50) 12.83±0.34a (125) 
15a 14.62±0.28a (75) 21.63±0.38a (100) 16.98±0.28a (50) 24.85±0.17a (75) 21.20±0.31a (100) 
16a 20.12±0.34a (100) 24.77±0.31a (75) 21.48±0.29a (100) 24.10±0.37a (100) 19.08±0.33a (100) 
17a 12.30±0.40a (125) 9.37±0.41a (150) 11.25±0.38a (175) 18.27±0.38a (125) 13.83±0.25a (150) 
18a 22.75±0.42a (75) 26.37±0.37a (100) 28.72±0.29c (100) 24.32±0.43a (100) 22.95±0.36a (100) 
Ofloxacin 28.48±0.37a (12.5) 31.12±0.14a (12.5) 31.55±0.19a (12.5) 32.22±0.20a (25) 29.98±0.29a (12.5) 
Negative 
Control 
0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
Values in parenthesis represent the corresponding MIC (μg/mL); ap < 0.0001, bp < 0.001, cp < 0.05, dp > 0.05 
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   Table 3: Antifungal activity data of the title compounds (1a-18a) against fungi 
 
Compound Zone of inhibition (mm ± SD and corresponding MIC (μg/mL)  
 
C. albicans A. niger A. flavus M. purpureous P. citrinum 
1a 18.88±0.33a (75) 21.52±0.31a (75) 17.30±0.23a (50) 15.05±0.38a (50) 20.38±0.41a (100) 
2a 22.77±0.39a (100) 14.50±0.34a (50) 19.45±0.34a (50) 18.43±0.35a (50) 19.18±0.40a (50) 
3a 22.58±0.32a (100) 21.95±0.39a (75) 25.90±0.33d (75) 24.47±0.36a (100) 28.13±0.29a (75) 
4a 19.37±0.44a (50) 20.28±0.40a (100) 17.53±0.35a (50) 18.27±0.38a (50) 21.53±0.47a (75) 
5a 24.17±0.37a (75) 27.08±0.26c (100) 20.45±0.50a (50) 27.70±0.16a (50) 23.35±0.38a (100) 
6a 20.67±0.52a (50) 16.92±0.55a (50) 23.15±0.34a (125) 20.30±0.35a (100) 22.13±0.32a (100) 
7a 23.18±0.34a (50) 22.53±0.36a (75) 26.20±0.27d (75) 27.10±0.43a (75) 24.87±0.60d (100) 
8a 17.25±0.38a (125) 24.42±0.40a (75) 17.97±3.09a (50) 16.97±0.48a (50) 16.67±0.41a (50) 
9a 25.28±0.37a (75) 27.50±0.20d (100) 25.53±0.30d (75) 21.27±0.35a (100) 19.87±0.34a (125) 
10a 27.78±0.44a (100) 26.32±0.39a (75) 24.85±0.45d (125) 27.83±0.32a (100) 27.18±0.28d (50) 
11a 24.62±0.45a (75) 22.73±0.42a (75) 26.62±0.43d (100) 20.75±0.36a (75) 24.32±0.33c (125) 
12a 22.20±0.35a (50) 18.80±0.50a (50) 17.33±0.40a (100) 22.40±0.41a (50) 19.28±0.34a (50) 
13a 16.65±0.40a (125) 23.15±0.30a (75) 18.22±0.38a (50) 14.07±0.38a (100) 23.82±0.27a (100) 
14a 14.13±0.28a (150) 19.78±0.43a (50) 23.97±0.25b (50) 18.98±0.32a (75) 21.60±0.32a (75) 
15a 25.60±0.32a (125) 22.22±0.35a (75) 20.53±0.44a (50) 26.92±0.28a (100) 28.17±0.27b (125) 
16a 24.50±0.34a (75) 27.03±0.27c (100) 26.90±0.34d (75) 22.03±0.41a (125) 18.10±0.39a (50) 
17a 26.32±0.36a (100) 27.28±0.25d (100) 24.22±0.29c (125) 19.60±0.42a (50) 20.32±0.45a (100) 
18a 18.27±0.34a (100) 17.83±0.46a (50) 21.17±0.34a (50) 24.23±0.25a (75) 15.78±0.28a (50) 
Ketoconazole 32.30±0.29a (12.5) 28.70±0.38a (12.5) 27.97±0.52a (25) 31.90±0.34a (12.5) 26.07±0.28a (25) 
Negative 
Control 
0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
 Values in parenthesis represent the corresponding MIC (μg/mL); ap < 0.0001, bp < 0.001, cp < 0.05 
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and they also had a higher MIC values than 
ofloxacin. Other compounds did not produced 
comparable antibacterial activity against Gram 
positive bacteria even at higher concentrations 
with respect to ofloxacin. 
 
The antibacterial activity of ofloxacin against 
Gram negative bacteria revealed that it has a 
MIC value of 12.5 μg/mL against E. coli; P. 
aeruginosa, K. pneumonia and P. vulgaris; and it 
has a MIC value of 25 μg/mL against B. 
bronchiseptica. The antibacterial activity of the 
title compounds (1a-18a) with respect to 
ofloxacin revealed that the compound 4a (MIC = 
75 μg/mL) displayed the highest activity of about 
90.83 % with p < 0.0001 against E. coli; the 
compounds 4a (MIC = 50 μg/mL) and 9a (MIC = 
100 μg/mL) displayed highest activity of about 
88.20 % and 88.46 %, respectively, with p < 
0.0001 against P. aeruginosa; the compound 18a 
(MIC = 100 μg/mL) displayed highest activity of 
about 91.03 % with p < 0.05 against K. 
pneumonia; the compound 10a (MIC = 100 
μg/mL) displayed highest activity of about 85.75 
% (p < 0.0001); and the compound 9a (MIC = 75 
μg/mL) displayed highest activity of about 92.72 
% (p < 0.0001) against P. vulgaris. The 
antibacterial activity produced by the compounds 
4a, 9a, 10a and 18a was lower than the 
antibacterial activity produced by ofloxacin and 
they also had a higher MIC value than ofloxacin. 
Other compounds did not produced comparable 
antibacterial activity against Gram negative 
bacteria even at higher concentrations with 
respect to ofloxacin. 
 
The antifungal activity of ketoconazole against 
fungi revealed that it has a MIC value of 12.5 
μg/mL against C. albicans, A. niger and M. 
purpureous; and it has a MIC value of 25 μg/mL 
against A. flavus and P. citrinum. The antifungal 
activity of the title compounds (1a-18a) with 
respect to ketoconazole revealed that the 
compound 10a (MIC = 100 μg/mL) displayed 
highest activity of about 86 % with p < 0.0001 
against C. albicans; the compounds 5a (MIC = 
100 μg/mL) and 16a (MIC = 100 μg/mL) 
displayed highest activity of about 94.35 % and 
94.18, respectively, with p < 0.05 against A. 
niger; the compound 17a (MIC = 125 μg/mL) 
displayed highest activity of about 86.59 % with p 
< 0.05 against A. flavus; the compounds 5a (MIC 
= 50 μg/mL), 7a (MIC = 75 μg/mL), and 10a (MIC 
= 100 μg/mL) displayed highest activity of about 
86.83, 84.95, and 87.24 %, respectively, with p < 
0.0001 against M. purpureous; and the 
compounds 3a (MIC = 75 μg/mL) and 15a (MIC 
= 125 μg/mL) displayed highest activity of about 
107.90 and 108.05 %, respectively, against P. 
citrinum. The antifungal activity produced by the 
compounds 3a and 15a was more than 
ketoconazole and statistically significant also. 
However, their MIC was also high. Some 
compounds exhibited good but statistically non-
significant antifungal activity (p > 0.05) with 
respect to ketoconazole, for example, the 
compound 9a (MIC = 100 μg/mL) and compound 
17a (MIC = 100 μg/mL), respectively, displayed 
about 95.81 and 95.05 % activity against A. 
niger; the compounds 3a (MIC = 75 μg/mL), 7a 
(MIC = 75 μg/mL), 9a (MIC = 75 μg/mL), 11a 
(MIC = 100 μg/mL), and 16a (MIC = 75 μg/mL), 
respectively, displayed activity of about 92.59, 
93.67, 91.27%, 97.17, and 96.17 % against A. 
flavus. The antifungal activity produced by the 
compounds 3a, 5a, 7a, 9a, 10a, 11a, 16a, and 
17a was lower than the antifungal activity 
produced by ketoconazole and they also had a 
higher MIC value than ketoconazole. Other 
compounds did not produced comparable 
antifungal activity against fungi even at higher 
concentrations with respect to ketoconazole. 
 
DISCUSSION 
 
A total of eighteen new compounds (1a-18a) 
were synthesized, and their structures were 
confirmed on the basis of their IR, 1H-NMR, 
Mass and elemental analysis data. The 
characteristic peaks in 1H-NMR spectra that 
confirmed the formation of the compounds (1a-
18a) from the compounds (1-18) [25] were the 
appearance of the signals at δ (ppm) values from 
2.63 to 2.72 for the four protons of –CH2-N-CH2- 
portion of the morpholine moiety; from 3.50 to 
3.58 for the four protons of –CH2-O-CH2- portion 
of the morpholin moiety; and from 4.27 to 4.42 
for the two methylene protons of –NH-CH2- 
moiety. The compounds (1a-18a) were tested for 
their in vitro antimicrobial activity by serial plate 
dilution method [27,28] against five Gram-
positive bacteria; five Gram-negative bacteria; 
and five fungi. 
 
Compound 3a (MIC = 75 µg/mL; p < 0.0001) and 
15a (MIC = 125 µg/mL; p < 0.001) produced 
superior antifungal activity than the standard 
drug, ketoconazole (MIC = 25 µg/mL; p < 
0.0001) against P. citrinum. Compound 4a (MIC  
= 100 μg/mL; p < 0.05) displayed highest but 
moderate activity against S. aureus with respect 
to the standard drug, ofloxacin (MIC = 25 µg/mL; 
p < 0.0001). Compound 4a (MIC = 75 μg/mL; p < 
0.0001) also exhibited highest but moderate 
activity against E. coli with respect to the 
standard drug, ofloxacin (MIC = 12.5 µg/mL; p < 
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0.0001). Further, compound 4a showed less 
activity than ofloxacin and also had higher MIC 
values than the standard drug ofloxacin. It is 
evident from the antimicrobial activity data 
mentioned in Table 1, Table 2, and Table 3 that 
the title compounds are better antifungal agents 
than antibacterial agents. This is contrary to our 
earlier reported work [25]. This shows that the 
addition of the morpholine moiety to these type of 
compounds [25] increases their antifungal 
activity. Accordingly, there is a possibility that the 
replacement of the morpholine moiety by its 
bioisosteres, for example piperidine moiety, in 
these compounds may also produce promising 
antifungal compounds.  Accordingly, this study 
may be extended to acquire more information 
about the structure activity relationships of these 
type of compounds. It is also believed that the 
synthesized compounds might be inhibiting the 
growth of all tested microorganism by same 
mechanism as earlier reported pyrimidine moiety 
containing drugs [15]. 
 
The structure activity relationship study of the 
title compounds (1a-18a) revealed that the chloro 
substitution with respect to positions 2, 3 and 5 of 
the phenyl ring along with a chloro/bromo 
substituted coumarin moiety are critical for 
activity against Gram positive bacteria; the 
chlorosubstitution with respect to positions 2, 3, 
and 4 of the phenyl ring along with a 
chloro/bromo substituted coumarin moiety are 
critical for activity against Gram negative 
bacteria; the chlorosubstitution with respect to 
positions 2, 4, and 6 of the phenyl ring along with 
a chloro substituted coumarin moiety are critical 
for activity against fungi; the chloro substitution at 
position 2 of the phenyl ring along with a 
chloro/bromo substituted coumarin moiety is 
relatively more critical for activity against Gram 
positive bacteria, Gram negative bacteria and 
fungi. 
 
CONCLUSION 
 
It is evident from the antimicrobial activity data of 
the title compounds (1a-18a) that the compounds 
3a and 15a produced higher antifungal activity 
than standard drug ketoconazole against P. 
citrinum. However, these compounds produced 
superior effect at higher concentration, and 
therefore, are considered to be less potent than 
ketoconazole. Some of the compounds displayed 
promising antibacterial activity at higher 
concentrations. It is also evident that the title 
compounds are better antifungal agents than as 
antibacterial agents. These compounds may be 
modified to achieve more potent antimicrobial 
activity. Accordingly, further studies to acquire 
more information about structure activity 
relationships are in progress in our laboratory. 
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